Business Context and Reporting Period
This Form 8-K was filed by Protagonist Therapeutics, Inc. on March 25, 2022. The report discloses the appointment of a new Chief Financial Officer, effective April 18, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $425,000 annually.
- Discretionary Bonus: Up to 40% of base salary.
- Equity Grants: 82,500 stock options and 13,750 Restricted Stock Units (RSUs).
Material Changes
The primary material change is the appointment of Asif Ali as Executive Vice President and Chief Financial Officer. Mr. Ali joins from Theravance Biopharma, Inc., where he served as Vice President, Finance and Chief Accounting Officer.
Outlook, Risks, and Unusual Items
Management Commentary: The Board approved the appointment to leverage Mr. Ali's experience in equity financings, strategic collaborations, and finance operations within the biopharmaceutical sector.
Equity Vesting: Options vest over four years (25% at one year, remainder monthly); RSUs vest in four equal annual installments.
Risks/Contingencies: No specific risks or contingencies are disclosed in this filing. The filing confirms no family relationships or undisclosed material interests exist between Mr. Ali and other company officers.
Investor Verification Checklist
- Confirm the effective start date of Mr. Ali's employment (April 18, 2022).
- Review the specific terms of the 2018 Inducement Plan governing the equity awards.
- Verify the vesting schedule details for the 82,500 options and 13,750 RSUs.
- Check subsequent filings for any changes to the executive compensation structure.